Article Text

Download PDFPDF

Gastroduodenal free papers
OC-098 How commonly is gastric cancer missed at endoscopy: a UK primary care based study
  1. S Menon1,
  2. A Dhar2,
  3. J Hoare3,
  4. N Trudgill4
  1. 1Department of Gastroenterology, New Cross Hospital, Wolverhampton, UK
  2. 2Department of Gastroenterology, Bishop Auckland Hospital and Darlington Memorial Hospital, Darlington, UK
  3. 3Department of Gastroenterology, St.Mary's Hospital, London, UK
  4. 4Department of Gastroenterology, Sandwell General Hospital, West Bromwich, UK


Introduction Meta-analysis of published single hospital series including 1977 subjects suggests that 14% of gastric cancer (GC) subjects have had an upper gastrointestinal endoscopy (OGD) up to 3 years previously that failed to diagnose their GC (50% in the 12 months before diagnosis and 50% 1–3 years before diagnosis).

Methods All patients with GC in the THIN general practice database covering 5 million UK subjects were examined. A nested case-control study was performed with cases subjects who underwent OGD 1–5 years prior to their OGD that diagnosed GC and controls subjects who did not undergo OGD 1–5 years prior to their diagnostic OGD.

Results 5473 GC were available for analysis (3402 males (62%), mean age 71 years), with follow-up of 46 779 subject years. 169 (3.1%, 98 males (58%), mean age 71 years) had an OGD which failed to diagnose GC between 1 and 5 years prior to diagnosis of GC, out of whom 128 (2.3%) had OGD between 1 and 3 years before and 41 (0.7%) had an OGD between 3 and 5 years before diagnosis. There were 56 primary care consultations with symptoms pertaining to oesophago-gastric cancer between 1 and 5 years prior to diagnosis of GC (dyspepsia (n) 51, anaemia 9, weight loss 12, dysphagia 3), of which all underwent OGD. No subject who had an OGD that did not diagnose cancer was on proton pump inhibitor (PPI) therapy in the year prior to OGD and 49 (0.9%) of subjects were on PPI therapy in the year prior to being diagnosed with GC. Logistic regression analysis of subjects who had an OGD that failed to diagnose cancer and those that did not, failed to identify any specific predictive factors (age 1.0 (0.99–1.01), p=0.99), sex 0.84 (0.61–1.14), p=0.26), related to an OGD that failed to diagnose GC.

Conclusion Missing GC at OGD is, reassuringly, less than half as common as previous much smaller studies in secondary care have suggested. PPI therapy does not contribute to missing GC at OGD. Advances in endoscopy and selection bias in previous studies may account for these differences.

Competing interests None declared.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.